242 related articles for article (PubMed ID: 34957309)
1.
Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
3.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
4. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, and
Choudhari RC; Kaur K; Das A; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
[TBL] [Abstract][Full Text] [Related]
6. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
7.
Rajagopal K; Kalusalingam A; Bharathidasan AR; Sivaprakash A; Shanmugam K; Sundaramoorthy M; Byran G
Molecules; 2023 May; 28(10):. PubMed ID: 37241915
[TBL] [Abstract][Full Text] [Related]
8. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
9. Interaction of marine Streptomyces compounds with selected cancer drug target proteins by in silico molecular docking studies.
Lankapalli AR; Kannabiran K
Interdiscip Sci; 2013 Mar; 5(1):37-44. PubMed ID: 23605638
[TBL] [Abstract][Full Text] [Related]
10. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer.
Suganya J; Radha M; Naorem DL; Nishandhini M
Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999
[TBL] [Abstract][Full Text] [Related]
11. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
Ashtekar SS; Bhatia NM; Bhatia MS
Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
13. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
[TBL] [Abstract][Full Text] [Related]
15. Marine-Derived Compounds as Potential Inhibitors of Hsp90 for Anticancer and Antimicrobial Drug Development: A Comprehensive In Silico Study.
Ouassaf M; Bourougaa L; Al-Mijalli SH; Abdallah EM; Bhat AR; A Kawsar SM
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138564
[TBL] [Abstract][Full Text] [Related]
16. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and
Lavanya KJ; Kaur K; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(4):374-383. PubMed ID: 36944620
[TBL] [Abstract][Full Text] [Related]
19. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components.
Singla R; Jaitak V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
